Scaling Up ADC Payloads

Join our latest webinar ‘Scaling up payload manufacturing for blockbuster ADCs.

Register free: https://www.pharmtech.com/pt_w/payloads

Event Overview:
Antibody-drug conjugates are a targeted approach to the treatment of cancer. As more of these complex products enter clinical development, the need to scale up production of their payloads becomes a pressing topic. In this webinar, participants will hear about Lonza’s investment in facilities capable of producing large quantities (100+ kg) under the strictest levels of containment.

• Market drivers
• Design concepts
• Facility overview

Key Learning Objectives:

• Key market trends
• Lonza’s approach to lifecycle investment
• Leadership in highly-potent API facility and process design

Who Should Attend:

• Key clients / potential clients from the ADC arena, covering all disciplines from biologics/ bioconjugation and payload-linker

Charles Johnson
Senior Director
Commercial Development
Lonza Small Molecules

Charles Johnson is the senior director of commercial development for Lonza Small Molecules. Charles has more than 20 years of experience in the pharmaceutical sector and specializes in antibody-drug conjugates. Prior to joining Lonza, Charles was CEO of ADC Biotechnology, which focuses on innovative immobilization technologies for protein conjugation and purification applications.

Register free: https://www.pharmtech.com/pt_w/payloads